Cellular Engineering: Hematopoietic Transplant, Immune Cell Therapy, and Regenerative Medicine

David H. McKenna, David F. Stroncek

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations


Mobilization agents can be used to stimulate normal donors for the collection of hematopoietic stem and progenitor cells, which can be used for transplantation, gene therapy, and regenerative medicine. Nonmobilized mononuclear cell collections can also be used for immune cell therapies, including genetically modified therapies such as chimeric antigen receptor T-cells. This chapter focuses on cell therapies derived from hematopoietic cells. The marrow product may be subjected to red cell or plasma depletion, cryopreservation, or other cellular engineering procedures. Umbilical cord blood can be collected in the delivery room immediately after the cord is clamped and while the placenta remains in the uterus, or after delivery when the placenta is taken to a nearby laboratory for collection. Adoptive immunotherapy has been used to treat malignancy, viral diseases, diseases with altered immunity, or autoimmune diseases.

Original languageEnglish (US)
Title of host publicationTransfusion Medicine
Subtitle of host publicationFifth Edition
Number of pages23
ISBN (Electronic)9781119599586
ISBN (Print)9781119599531
StatePublished - Jan 1 2021

Bibliographical note

Publisher Copyright:
© 2021 John Wiley and Sons Ltd.


Dive into the research topics of 'Cellular Engineering: Hematopoietic Transplant, Immune Cell Therapy, and Regenerative Medicine'. Together they form a unique fingerprint.

Cite this